The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Meloxicam Drug Market Research Report 2024
Synopsis
Meloxicam (Mobic) is used to treat pain or inflammation caused by osteoarthritis or rheumatoid arthritis.
The global Meloxicam Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Meloxicam Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Meloxicam Drug.
Report Scope
The Meloxicam Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Meloxicam Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Meloxicam Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Boehringer-Ingelheim
TerSera Therapeutics
Iroko Pharmaceuticals
Apotex
Yung Shin Pharmaceutical
Breckenridge Pharmaceutical
Zydus Pharmaceuticals
Unichem Pharmaceuticals
Strides Pharma
Cipla
Dr. Reddy's Laboratories
Glenmark Pharmaceuticals
Teva
PuraCap Pharmaceutical
TARO
Lupin Pharmaceuticals
Aurobindo Pharma
Segment by Type
Tablet
Capsule
Segment by Application
Osteoarthritis in Adults (OA)
Rheumatoid Arthritis in Adults (RA)
Pediatric Patients
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Meloxicam Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Meloxicam Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Meloxicam (Mobic) is used to treat pain or inflammation caused by osteoarthritis or rheumatoid arthritis.
The global Meloxicam Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Meloxicam Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Meloxicam Drug.
Report Scope
The Meloxicam Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Meloxicam Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Meloxicam Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Boehringer-Ingelheim
TerSera Therapeutics
Iroko Pharmaceuticals
Apotex
Yung Shin Pharmaceutical
Breckenridge Pharmaceutical
Zydus Pharmaceuticals
Unichem Pharmaceuticals
Strides Pharma
Cipla
Dr. Reddy's Laboratories
Glenmark Pharmaceuticals
Teva
PuraCap Pharmaceutical
TARO
Lupin Pharmaceuticals
Aurobindo Pharma
Segment by Type
Tablet
Capsule
Segment by Application
Osteoarthritis in Adults (OA)
Rheumatoid Arthritis in Adults (RA)
Pediatric Patients
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Meloxicam Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Meloxicam Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Meloxicam Drug Market Overview
1.1 Product Overview and Scope of Meloxicam Drug
1.2 Meloxicam Drug Segment by Type
1.2.1 Global Meloxicam Drug Market Value Comparison by Type (2024-2030)
1.2.2 Tablet
1.2.3 Capsule
1.3 Meloxicam Drug Segment by Application
1.3.1 Global Meloxicam Drug Market Value by Application: (2024-2030)
1.3.2 Osteoarthritis in Adults (OA)
1.3.3 Rheumatoid Arthritis in Adults (RA)
1.3.4 Pediatric Patients
1.4 Global Meloxicam Drug Market Size Estimates and Forecasts
1.4.1 Global Meloxicam Drug Revenue 2019-2030
1.4.2 Global Meloxicam Drug Sales 2019-2030
1.4.3 Global Meloxicam Drug Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Meloxicam Drug Market Competition by Manufacturers
2.1 Global Meloxicam Drug Sales Market Share by Manufacturers (2019-2024)
2.2 Global Meloxicam Drug Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Meloxicam Drug Average Price by Manufacturers (2019-2024)
2.4 Global Meloxicam Drug Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Meloxicam Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Meloxicam Drug, Product Type & Application
2.7 Meloxicam Drug Market Competitive Situation and Trends
2.7.1 Meloxicam Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Meloxicam Drug Players Market Share by Revenue
2.7.3 Global Meloxicam Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Meloxicam Drug Retrospective Market Scenario by Region
3.1 Global Meloxicam Drug Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Meloxicam Drug Global Meloxicam Drug Sales by Region: 2019-2030
3.2.1 Global Meloxicam Drug Sales by Region: 2019-2024
3.2.2 Global Meloxicam Drug Sales by Region: 2025-2030
3.3 Global Meloxicam Drug Global Meloxicam Drug Revenue by Region: 2019-2030
3.3.1 Global Meloxicam Drug Revenue by Region: 2019-2024
3.3.2 Global Meloxicam Drug Revenue by Region: 2025-2030
3.4 North America Meloxicam Drug Market Facts & Figures by Country
3.4.1 North America Meloxicam Drug Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Meloxicam Drug Sales by Country (2019-2030)
3.4.3 North America Meloxicam Drug Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Meloxicam Drug Market Facts & Figures by Country
3.5.1 Europe Meloxicam Drug Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Meloxicam Drug Sales by Country (2019-2030)
3.5.3 Europe Meloxicam Drug Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Meloxicam Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Meloxicam Drug Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Meloxicam Drug Sales by Country (2019-2030)
3.6.3 Asia Pacific Meloxicam Drug Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Meloxicam Drug Market Facts & Figures by Country
3.7.1 Latin America Meloxicam Drug Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Meloxicam Drug Sales by Country (2019-2030)
3.7.3 Latin America Meloxicam Drug Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Meloxicam Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Meloxicam Drug Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Meloxicam Drug Sales by Country (2019-2030)
3.8.3 Middle East and Africa Meloxicam Drug Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Meloxicam Drug Sales by Type (2019-2030)
4.1.1 Global Meloxicam Drug Sales by Type (2019-2024)
4.1.2 Global Meloxicam Drug Sales by Type (2025-2030)
4.1.3 Global Meloxicam Drug Sales Market Share by Type (2019-2030)
4.2 Global Meloxicam Drug Revenue by Type (2019-2030)
4.2.1 Global Meloxicam Drug Revenue by Type (2019-2024)
4.2.2 Global Meloxicam Drug Revenue by Type (2025-2030)
4.2.3 Global Meloxicam Drug Revenue Market Share by Type (2019-2030)
4.3 Global Meloxicam Drug Price by Type (2019-2030)
5 Segment by Application
5.1 Global Meloxicam Drug Sales by Application (2019-2030)
5.1.1 Global Meloxicam Drug Sales by Application (2019-2024)
5.1.2 Global Meloxicam Drug Sales by Application (2025-2030)
5.1.3 Global Meloxicam Drug Sales Market Share by Application (2019-2030)
5.2 Global Meloxicam Drug Revenue by Application (2019-2030)
5.2.1 Global Meloxicam Drug Revenue by Application (2019-2024)
5.2.2 Global Meloxicam Drug Revenue by Application (2025-2030)
5.2.3 Global Meloxicam Drug Revenue Market Share by Application (2019-2030)
5.3 Global Meloxicam Drug Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Boehringer-Ingelheim
6.1.1 Boehringer-Ingelheim Corporation Information
6.1.2 Boehringer-Ingelheim Description and Business Overview
6.1.3 Boehringer-Ingelheim Meloxicam Drug Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Boehringer-Ingelheim Meloxicam Drug Product Portfolio
6.1.5 Boehringer-Ingelheim Recent Developments/Updates
6.2 TerSera Therapeutics
6.2.1 TerSera Therapeutics Corporation Information
6.2.2 TerSera Therapeutics Description and Business Overview
6.2.3 TerSera Therapeutics Meloxicam Drug Sales, Revenue and Gross Margin (2019-2024)
6.2.4 TerSera Therapeutics Meloxicam Drug Product Portfolio
6.2.5 TerSera Therapeutics Recent Developments/Updates
6.3 Iroko Pharmaceuticals
6.3.1 Iroko Pharmaceuticals Corporation Information
6.3.2 Iroko Pharmaceuticals Description and Business Overview
6.3.3 Iroko Pharmaceuticals Meloxicam Drug Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Iroko Pharmaceuticals Meloxicam Drug Product Portfolio
6.3.5 Iroko Pharmaceuticals Recent Developments/Updates
6.4 Apotex
6.4.1 Apotex Corporation Information
6.4.2 Apotex Description and Business Overview
6.4.3 Apotex Meloxicam Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Apotex Meloxicam Drug Product Portfolio
6.4.5 Apotex Recent Developments/Updates
6.5 Yung Shin Pharmaceutical
6.5.1 Yung Shin Pharmaceutical Corporation Information
6.5.2 Yung Shin Pharmaceutical Description and Business Overview
6.5.3 Yung Shin Pharmaceutical Meloxicam Drug Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Yung Shin Pharmaceutical Meloxicam Drug Product Portfolio
6.5.5 Yung Shin Pharmaceutical Recent Developments/Updates
6.6 Breckenridge Pharmaceutical
6.6.1 Breckenridge Pharmaceutical Corporation Information
6.6.2 Breckenridge Pharmaceutical Description and Business Overview
6.6.3 Breckenridge Pharmaceutical Meloxicam Drug Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Breckenridge Pharmaceutical Meloxicam Drug Product Portfolio
6.6.5 Breckenridge Pharmaceutical Recent Developments/Updates
6.7 Zydus Pharmaceuticals
6.6.1 Zydus Pharmaceuticals Corporation Information
6.6.2 Zydus Pharmaceuticals Description and Business Overview
6.6.3 Zydus Pharmaceuticals Meloxicam Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Zydus Pharmaceuticals Meloxicam Drug Product Portfolio
6.7.5 Zydus Pharmaceuticals Recent Developments/Updates
6.8 Unichem Pharmaceuticals
6.8.1 Unichem Pharmaceuticals Corporation Information
6.8.2 Unichem Pharmaceuticals Description and Business Overview
6.8.3 Unichem Pharmaceuticals Meloxicam Drug Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Unichem Pharmaceuticals Meloxicam Drug Product Portfolio
6.8.5 Unichem Pharmaceuticals Recent Developments/Updates
6.9 Strides Pharma
6.9.1 Strides Pharma Corporation Information
6.9.2 Strides Pharma Description and Business Overview
6.9.3 Strides Pharma Meloxicam Drug Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Strides Pharma Meloxicam Drug Product Portfolio
6.9.5 Strides Pharma Recent Developments/Updates
6.10 Cipla
6.10.1 Cipla Corporation Information
6.10.2 Cipla Description and Business Overview
6.10.3 Cipla Meloxicam Drug Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Cipla Meloxicam Drug Product Portfolio
6.10.5 Cipla Recent Developments/Updates
6.11 Dr. Reddy's Laboratories
6.11.1 Dr. Reddy's Laboratories Corporation Information
6.11.2 Dr. Reddy's Laboratories Meloxicam Drug Description and Business Overview
6.11.3 Dr. Reddy's Laboratories Meloxicam Drug Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Dr. Reddy's Laboratories Meloxicam Drug Product Portfolio
6.11.5 Dr. Reddy's Laboratories Recent Developments/Updates
6.12 Glenmark Pharmaceuticals
6.12.1 Glenmark Pharmaceuticals Corporation Information
6.12.2 Glenmark Pharmaceuticals Meloxicam Drug Description and Business Overview
6.12.3 Glenmark Pharmaceuticals Meloxicam Drug Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Glenmark Pharmaceuticals Meloxicam Drug Product Portfolio
6.12.5 Glenmark Pharmaceuticals Recent Developments/Updates
6.13 Teva
6.13.1 Teva Corporation Information
6.13.2 Teva Meloxicam Drug Description and Business Overview
6.13.3 Teva Meloxicam Drug Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Teva Meloxicam Drug Product Portfolio
6.13.5 Teva Recent Developments/Updates
6.14 PuraCap Pharmaceutical
6.14.1 PuraCap Pharmaceutical Corporation Information
6.14.2 PuraCap Pharmaceutical Meloxicam Drug Description and Business Overview
6.14.3 PuraCap Pharmaceutical Meloxicam Drug Sales, Revenue and Gross Margin (2019-2024)
6.14.4 PuraCap Pharmaceutical Meloxicam Drug Product Portfolio
6.14.5 PuraCap Pharmaceutical Recent Developments/Updates
6.15 TARO
6.15.1 TARO Corporation Information
6.15.2 TARO Meloxicam Drug Description and Business Overview
6.15.3 TARO Meloxicam Drug Sales, Revenue and Gross Margin (2019-2024)
6.15.4 TARO Meloxicam Drug Product Portfolio
6.15.5 TARO Recent Developments/Updates
6.16 Lupin Pharmaceuticals
6.16.1 Lupin Pharmaceuticals Corporation Information
6.16.2 Lupin Pharmaceuticals Meloxicam Drug Description and Business Overview
6.16.3 Lupin Pharmaceuticals Meloxicam Drug Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Lupin Pharmaceuticals Meloxicam Drug Product Portfolio
6.16.5 Lupin Pharmaceuticals Recent Developments/Updates
6.17 Aurobindo Pharma
6.17.1 Aurobindo Pharma Corporation Information
6.17.2 Aurobindo Pharma Meloxicam Drug Description and Business Overview
6.17.3 Aurobindo Pharma Meloxicam Drug Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Aurobindo Pharma Meloxicam Drug Product Portfolio
6.17.5 Aurobindo Pharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Meloxicam Drug Industry Chain Analysis
7.2 Meloxicam Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Meloxicam Drug Production Mode & Process
7.4 Meloxicam Drug Sales and Marketing
7.4.1 Meloxicam Drug Sales Channels
7.4.2 Meloxicam Drug Distributors
7.5 Meloxicam Drug Customers
8 Meloxicam Drug Market Dynamics
8.1 Meloxicam Drug Industry Trends
8.2 Meloxicam Drug Market Drivers
8.3 Meloxicam Drug Market Challenges
8.4 Meloxicam Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
